SNPX

Synaptogenix

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SNPX

Synaptogenix, Inc.

A clinical-stage biopharmaceutical company that developing new therapies for neurodegenerative diseases

Industry

Pharmaceutical

Established Date

10/31/2012

Listing Date

06/07/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.synaptogen.com

Security Type

Common stock

Office address

1185 Avenue of the Americas, 3rd Floor , New York, New York 10036

Business

Introduction

Synaptogenix, Inc., was incorporated in Delaware on October 31, 2012. The company is a biopharmaceutical company with product candidates in preclinical and clinical development. The Company is primarily focused on developing a product platform based on a drug candidate called Bryostatin-1, synthesized from a natural product (bryostatin) isolated from marine invertebrate organisms for the treatment of Alzheimer's disease (" AD "), which is in clinical testing.

Company Financials

EPS

SNPX has released its 2023 Q3 earnings. EPS was reported at -0.03, versus the expected 0.00, missing expectations. The chart below visualizes how SNPX has performed over recent quarters, highlighting trends in earnings surprises.